Search

Your search keyword '"Satomi, Ryosuke"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Satomi, Ryosuke" Remove constraint Author: "Satomi, Ryosuke"
136 results on '"Satomi, Ryosuke"'

Search Results

1. Quantification of escape from X chromosome inactivation with single-cell omics data reveals heterogeneity across cell types and tissues

2. Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study

3. DOCK2 is involved in the host genetics and biology of severe COVID-19

4. The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

8. Cough and sputum in long COVID are associated with severe acute COVID-19: a Japanese cohort study

9. Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy

10. Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors

11. Development of Personalized Combination Cancer Immunotherapy Based on the Patients’ Immune Status

12. Supplementary Figure S4 from Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

13. Data from Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

14. Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments

15. Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

17. Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody

19. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer

20. Comprehensive Analysis of Long COVID in a Japanese Nationwide Prospective Cohort Study

21. DOCK2 is involved in the host genetics and biology of severe COVID-19

25. sj-docx-3-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

26. sj-doc-1-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

27. sj-docx-8-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

28. sj-docx-4-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

29. sj-docx-6-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

30. sj-docx-5-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

31. sj-docx-2-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

32. sj-docx-7-pmj-10.1177_02692163211001721 – Supplemental material for Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

33. Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

36. Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

37. An Adult Case of Pulmonary Artery Sling Accompanied by Tracheobronchomalacia

38. DOCK2is involved in the host genetics and biology of severe COVID-19

39. Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

40. Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib

41. Methylation‐induced downregulation ofTFPI‐2causesTMPRSS4overexpression and contributes to oncogenesis in a subset of non‐small‐cell lung carcinoma

42. Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC

43. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma

44. Abstract 5652: Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.

46. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients

47. The Combination of Multiple Receptor Tyrosine Kinase Inhibitor and Mammalian Target of Rapamycin Inhibitor Overcomes Erlotinib Resistance in Lung Cancer Cell Lines through c-Met Inhibition

48. Abstract 5302: Overcoming cancer immune evasion in lung carcinoma using EGFR-TKI (Gefitinib)

49. FOXD1 expression is associated with poor prognosis in non-small cell lung cancer.

50. Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors.

Catalog

Books, media, physical & digital resources